5-methoxy-3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 5-methoxy-3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridine
• 英文别名: 5-methoxy-3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperdin-1-yl]methyl}phenyl)-1,6-naphthyridme；5-methoxy-3-phenyl-2-[4-[[4-(3-pyridin-2-yl-1H-1,2,4-triazol-5-yl)piperidin-1-yl]methyl]phenyl]-1,6-naphthyridine
• 化学式: C₃₄H₃₁N₇O
• 分子量: 553.666
• InChiKey: RVKXKIKWMPJFIG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  42
• 可旋转键数：
  7
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  92.7
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5-methoxy-3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridine 在 盐酸 、 水 作用下， 以 四氢呋喃 为溶剂， 生成 3-苯基-2-[4-[[4-[5-(2-吡啶)-1H-1,2,4-三唑-3-基]-1-哌啶]甲基]苯基]-1,6-萘啶-5(6H)-酮
  参考文献：
  名称：

  发现有效的和具有细胞活性的变构双Akt 1和2抑制剂。

  摘要：

  本文描述了一种变构性Akt 1和2抑制剂对细胞效能的改善。关键发现包括鉴定分子的溶剂暴露区域和附加碱性胺以增强分子的物理化学性质。讨论了结构-活性关系的发现。

  DOI：

  10.1016/j.bmcl.2008.05.085
• 作为产物：
  描述：

  2-氯-4-氨基吡啶 在 盐酸 、 水 、 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 、 正戊烷 为溶剂， 反应 19.17h， 生成 5-methoxy-3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridine
  参考文献：
  名称：

  WO2006/135627

  摘要：

  公开号：

文献信息

• Inhibitors of Akt Activity
  申请人：Arruda Jeannie M.

  公开号：US20080287457A1

  公开（公告）日：2008-11-20

  The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.

  本发明涉及含有取代萘啶的化合物，其抑制Akt蛋白激酶的活性。本发明还涉及含有本发明化合物的化疗组合物以及治疗癌症的方法，包括给予本发明化合物的治疗方法。这些取代萘啶与PCT出版物WO2003/086394中报告的其他萘啶相比具有意外的优点，这些意外的优点可能包括增强的细胞效力/溶解度、更大的选择性、增强的药代动力学性质、缺乏非靶标活性等。
• Inhibitors of akt activtiy
  申请人：Armstrong Donna J.

  公开号：US20100222321A1

  公开（公告）日：2010-09-02

  The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

  本发明提供了一种取代萘啶化合物，其抑制Akt活性。特别地，所披露的化合物选择性地抑制一种或两种Akt同工酶。本发明还提供了包含这种抑制剂化合物的组合物和通过将该化合物用于需要癌症治疗的患者中来抑制Akt活性的方法。
• Inhibitors of Akt activity
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07910561B2

  公开（公告）日：2011-03-22

  The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.

  本发明涉及含有取代萘啶的化合物，其能够抑制Akt酶的活性，Akt酶是一种丝氨酸/苏氨酸蛋白激酶。本发明还涉及包含本发明化合物的化疗组合物以及治疗癌症的方法，包括给予本发明化合物的治疗。与PCT出版物WO2003/086394中报道的其他萘啶相比，这些取代萘啶具有意外的优势特性，这些意外的优势特性可能包括增加的细胞效力/溶解度，更强的选择性，增强的药代动力学特性，缺乏非特异性作用等。
• [EN] INHIBITORS OF AKT ACTIVITY<br/>[FR] INHIBITEURS D'ACTIVITE AKT
  申请人：MERCK & CO INC

  公开号：WO2006065601A3

  公开（公告）日：2007-08-09
• Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model
  作者：Mark T. Bilodeau、Adrienne E. Balitza、Jacob M. Hoffman、Peter J. Manley、Stanley F. Barnett、Deborah Defeo-Jones、Kathleen Haskell、Raymond E. Jones、Karen Leander、Ronald G. Robinson、Anthony M. Smith、Hans E. Huber、George D. Hartman

  DOI：10.1016/j.bmcl.2008.04.074

  日期：2008.6

  A series of naphthyridine and naphthyridinone allosteric dual inhibitors of Akt1 and 2 have been developed. These compounds have been optimized to have potent dual activity against the activated kinase as well as the activation of Akt in cells. One molecule in particular, compound 17, has potent inhibitory activity against Akt1 and 2 in vivo in a mouse lung and efficacy in a tumor xenograft model. (C) 2008 Elsevier Ltd. All rights reserved.